David Moller has joined Sigilon Therapeutics to become the company’s chief scientific officer. Moller comes to the Cambridge, MA, drug developer from Eli Lilly (NYSE: LLY), where he was vice president of business development for emerging technology and innovation. Last year, Sigilon raised $23.5 million in a Series A financing round to bring its technology for encapsulating therapeutic proteins into clinical testing.
Sponsored · Whitepaper
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson
Sponsored · Whitepaper
How incorporating more virtual/hybrid trials and decentralized research into clinical development can better integrate healthcare into patients’ real lives and accelerate approval of new medications.
Medpace
From Our Editors · Special Report
The AI, Big Data, and R&D Boom
